Toray Industries (3402) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
26 Mar, 2026Progress on financial and operational targets
Core operating income increased by 54 billion yen since FY 2022, driven by structural reforms, but remains below target due to lower sales in Performance Chemicals and Carbon Fiber Composite Materials.
ROIC is expected to reach about 5% in FY 2025, meeting the target, while ROE will fall short.
All segments except Life Science saw improved core operating income and ROIC; Environment & Engineering led with 11% ROIC.
Strategic pricing and the Darwin Project contributed to a 30 billion yen increase in profitability.
Business strategy and portfolio management
Business segments were realigned, combining water treatment and healthcare to accelerate growth in health and comfort markets.
The business portfolio is managed by growth potential, profitability, and competitiveness, with a focus on next-generation markets like semiconductors and space.
Structural reform businesses' invested capital ratio is targeted to drop below 10% by FY 2028.
Continuous innovation and strategic pricing are emphasized to create highly profitable businesses.
Medium- and long-term management programs
IGNITION 2028 aims for deeper growth and faster reform, targeting ROIC of about 7% and core operating income of 230 billion yen by FY 2028.
The long-term strategy, "TORAY Challenges 2035," seeks to achieve an ROIC of about 10% by delivering value in next-generation markets.
Key management measures include business competitiveness, optimal capital allocation, innovation, cost competitiveness, and human capital management.
Latest events from Toray Industries
- Profit fell sharply on battery separator film impairment, but full-year outlook was raised.3402
Q3 202613 Feb 2026 - Q1 profit and revenue jumped, driving a raised FY2025 outlook amid global risks.3402
Q1 20252 Feb 2026 - Profit and revenue surged on strong chemicals and water treatment, with guidance maintained.3402
Q3 20258 Jan 2026 - Revenue and profit fell, but buybacks, dividend hike, and reforms support capital efficiency.3402
Q2 202623 Dec 2025 - Revenue and profit fell, but guidance and dividend outlook remain steady amid market headwinds.3402
Q1 202623 Nov 2025 - Profit and cash flow surged, with further growth expected despite global risks.3402
Q4 202517 Nov 2025 - Record H1 profit and raised full-year outlook, with a 100B yen share buyback approved.3402
Q2 202513 Jun 2025